EGFR and neoplasm: In addition, to test the therapeutic effect of targeted sumIL-2 therapy, we also generated mouse tumor cell lines preferentially expressing mouse EGFR with few site mutations which can be recognized by Cetuximab, the FDA-approved anti-human EGFR antibody for proof of concept of tumor targeting.